CrossPac is engaged in in-licensing and out-licensing activities of pharmaceutical and biotech products. The company's core strategy is to identify innovative early-stage pharmaceutical and biotech products that are suitable for R&D development in China, utilize the lower costs R&D resources of its affiliated companies in China, and quickly bring the drug candidates from preclinical to clinical stages in China. The company then chooses those products with promising clinical data and collaborates with its partners in US and Europe for further development in the global markets. CrossPac Group Ltd is a subsidiary of the China Medical System Holdings Limited.